Advertisement

Journal of Parasitic Diseases

, Volume 40, Issue 3, pp 922–929 | Cite as

Cytokine patterns in experimental schistosomiasis mansoni infected mice treated with silymarin

  • Nagwa Mostafa El-Sayed
  • Ghada Mahmoud Fathy
  • Sara Abdel-Rahman Abdel-Rahman
  • Mahmoud Abdel-Atei El-Shafei
Original Article
  • 170 Downloads

Abstract

The purpose of this study was to determine cytokine patterns in experimental schistosomiasis mansoni infected mice treated with silymarin. The study was conducted upon 100 mice that were divided into five groups; 20 each: uninfected control group, Schistosoma mansoni infected untreated mice (infected control), infected mice treated with praziquantel (PZQ), infected mice treated with silymarin and infected mice treated with both praziquantel and silymarin. 10 mice from each group were sacrificed at 10th and 18th weeks post infection respectively. Histopathological investigations were performed. Liver sections were stained with hematoxylin–eosin and Masson’s trichrome stain to evaluate changes of granuloma sizes and numbers. Serum levels of the cytokines (TNF-α, IFN-γ, IL-4 and TGF-β1) were assessed in the sera of all groups by immunoassay. The measured levels of cytokines (IFN-γ, IL-4, TNF-α, TGF-β1) were found to be significantly increased in infected mice compared to normal control. At the same time, treated groups with silymarin alone or combined with PZQ showed significant decrease in IL-4, TNF-α and TGF-β1 levels compared to infected control. On the other hand, there was a significant increase in IFN-γ level observed in all treated groups compared to infected control. In addition, the histopathological examination of the liver in the group treated with PZQ showed a reduction in the number of livers eggs granuloma at all periods of sacrification compared with the infected untreated group. However, there was more decrease in granulomas diameter in both silymarin treated group or combined with PZQ at all periods of sacrification when compared to infected untreated group. In conclusion; treatment with silymarin combined with PZQ in murine schistosomiasis could reduce hepatic fibrosis by their action on the production of pro-inflammatory cytokines.

Keywords

Schistosomamansoni Liver fibrosis Cytokines Silymarin Praziquantel 

References

  1. Abath FG, Morais CN, Montenegro CE, Wynn TA, Montenegro SM (2006) Immunopathogenic mechanisms in schistosomasis: what can be learnt from human studies? Trends Parasitol 22(2):85–91CrossRefGoogle Scholar
  2. Afdhal NH, Nunes D (2004) Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 99(6):1160–1174CrossRefGoogle Scholar
  3. Alves-Oliveira LF, Moreno EC, Gazzinelli G, Martins-Filho AO, Silveira AMS, Gazzinelli A, Malaquias LCC, LoVerde P, Martins Leite P, Correa-Oliveira R (2006) Cytokine production associated with periportal fibrosis during chronic schistosomiasis mansoni in humans. Infect Immun 74(2):1215–1221CrossRefPubMedCentralGoogle Scholar
  4. Booth M, Mwatha JK, Joseph S, Jones FM, Kadzo H, Ireri E, Kazibwe F, Kemijumbi J, Kariuki C, Kimani G, Ouma JH, Kabatereine NB, Vennervald BJ, Dunne DW (2004) Periportal fibrosis in human Schistosoma mansoni infection is associated with low IL-10, low IFN-gamma, high TNF-alpha, or low RANTES, depending on age and gender. J Immunol 172(2):1295–1303CrossRefGoogle Scholar
  5. Boros DL (1994) The role of cytokines in the formation of the schistosome egg granuloma. Immunobiology 191(4–5):441–450CrossRefGoogle Scholar
  6. Boros DL, Lukacs NW (1992) The role of egg antigens, cytokines in granuloma formation in murine schistosomiasis mansoni. Mem Inst Oswaldo Cruz 87(4):75–79CrossRefGoogle Scholar
  7. Brito CF, Caldas IR, Coura Filho P, Corrêa-Oliveira R, Oliveira SC (2000) CD4+T cells of schistosomiasis naturally resistant individuals living in an endemic area produce interferon-γ and tumor necrosis factor-α in response to the recombinant 14KDA Schistosoma mansoni fatty acid-binding protein. Scand J Immunol 51(6):595–601CrossRefGoogle Scholar
  8. Burke ML, Jones MK, Gobert GN, Li YS, Ellis MK, McManus DP (2009) Immunopathogenesis of human schistosomiasis. Parasite Immunol 31(4):163–176CrossRefGoogle Scholar
  9. Burke ML, McManus DP, Ramm A, Duke M, Li Y, Jones MK, Gobert GN (2010) Temporal expression of chemokines dictates the hepatic inflammatory infiltrate in a murine model of schistosomiasis. PLoS Negl Trop Dis 4(2):e598CrossRefPubMedCentralGoogle Scholar
  10. Caldas IR, Campi-Azevedoa AC, Oliveirab LFA, Silveirab AMS, Rodrigo C, Oliveiraa RC, Gazzinellia G (2008) Human schistosomiasis mansoni: immune responses during acute and chronic phases of the infection. Acta Trop 108(2–3):109–117CrossRefGoogle Scholar
  11. Chiaramonte G, Cheever AW, Malley JD, Donaldson DD, Wynn TA (2001) Studies of murine schistosomiasis reveal interleukin-13 blockade as a treatment for established and progressive liver fibrosis. Hepatology 34:273–282CrossRefGoogle Scholar
  12. Corrêa-Oliveira R, Rodrigues Caldas I, Martins-Filho OA, Carvalho Queiroz C, Lambertucci JR, Renan Cunha-Melo J, Soares Silveira A, Prata A, Wilson A, Gazzinelli G (2000) Analysis of the effects of treatment of human Schistosoma mansoni infection on the immune response of patients from endemic areas. Acta Trop 77(1):141–146CrossRefGoogle Scholar
  13. de Jesus AR, Magalhaes A, Miranda DG, Miranda RG, Araujo MI, De Jesus AA, Silva A, Santana LB, Pearce E, Carvalho EM (2004) Association of type 2 cytokines with hepatic fibrosis in human Schistosoma mansoni infection. Infect Immun 72(6):3391–3397CrossRefGoogle Scholar
  14. El-Ahwany EG, Nosseir MM, Ali LR (2006) Immunomodulation of pulmonary and hepatic grnaulomatous response in mice immunized with purified lung-stage schistosomulae antigen. J Egypt Soc Parasitol 36:335–350Google Scholar
  15. El-Lakkany N, Nosseir M (2007) Pharmaco dynamics of pentoxifylline and/or praziquantel in murine schistosomiasis mansoni. APMIS 115(3):184–194CrossRefGoogle Scholar
  16. El-Lakkany NM, Hamman OA, El-Maadawy WH, Badawy AA, Ain-Shoka AA, Ebeid FA (2012) Anti-inflammatory/anti-fibrotic effects of the hepatoprotective silymarin and the schistosomicide praziquantel against Schistosoma mansoni-induced liver fibrosis. Parasit Vectors 5:9CrossRefPubMedCentralGoogle Scholar
  17. Gonnert R, Andrews P (1977) Praziquantel, a new broad-spectrum antischistosomal agent. Z Parasitenk 52(2):129–150CrossRefGoogle Scholar
  18. Henri S, Chevillard C, Mergani A, Paris P, Gaudart J, Camilla C, Dessein H, Montero F, Elwali NE, Saeed OK, Magzoub M, Dessein AJ (2002) Cytokine regulation of periportal fibrosis in humans infected with Schistosoma: IFN-gamma is associated with protection against fibrosis and TNF-alpha with aggravation of disease. J Immunol 169(2):929–936CrossRefGoogle Scholar
  19. Hoff J, Rlagt LV (2000) Methods of blood collection in the mouse. Lab Anim 29(10):47–53Google Scholar
  20. Hoffmann KF, Caspar P, Cheever AW, Wynn TA (1998) IFN gamma, IL-12, and TNF-alpha are required to maintain reduced liver pathology in mice vaccinated with Schistosoma mansoni eggs and IL-12. J Immunol 161(8):4201–4210Google Scholar
  21. Hoffmann KF, Wynn TA, Dunne DW (2002) Cytokine mediated host responses during schistosome infections: walking the fine line between immunological control and immunopathology. Adv Parasitol 52:265–307CrossRefGoogle Scholar
  22. Johnson VJ, Osuchowski MF, He Q, Sharma RP (2002) Physiological responses to a natural antioxidant flavonoid mixture, silymarin, in BALB/c mice: II. Alterations in thymic differentiation correlate with changes in c-myc gene expression. Planta Med 68(11):961–965CrossRefGoogle Scholar
  23. Kanzler S, Lohse AW, Keil A, Henninger J, Dienes HP, Schirmacher P, Rose-John S, Zum Büschenfelde KHM, Blessing M (1999) TGF-β1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis. Am J Physiol Gastrointest Liver Physiol 276(2):1059–1068CrossRefGoogle Scholar
  24. Kato K, Miura M (1954) On the comparison of some stool examination methods. Jpn J Parasitol 3:35Google Scholar
  25. Kihara JH, Muhoho N, Njomo D, Mwobobia IK, Josyline K, Mitsui Y, Awazawa T, Amano T, Mwandawiro C (2007) Drug efficacy of praziquantel and albendazole in school children in Mwea division, Central Province, Kenya. Acta Tropica 102(3):165–171CrossRefGoogle Scholar
  26. Kitani A, Fuss I, Nakamura K, Kumaki F, Usui T, Strober W (2003) Transforming growth factor (TGF-β1) producing regulatory T cells induce Smad-mediated interleukin 10 secretion that facilitates coordinated immunoregulatory activity and amelioration of TGF-β1 mediated fibrosis. J Exp Med 198(8):1179–1188CrossRefPubMedCentralGoogle Scholar
  27. Kresina TF, He Q, Zern MA (1992) Cytokines, hepatic fibrosis and schistosomiasis. R I Med 75:191–195Google Scholar
  28. Liang Y-S, Bruce JI, Boyd DA (1987) Laboratory cultivation of schistosome vector snails and maintenance of schistosome life cycles In: Proceedings of the first Sino-American symposium, Santa Cruz, pp 34–48Google Scholar
  29. Liu X, Kohyama T, Wang H, Zhu YK, Wen F-Q, Kim HJ, Romberger DJ, Rennard SI (2002) Th2 cytokine regulation of type I collagen gel contraction mediated by human lung mesenchymal cells. Am J Physiol 282(5):L1049–L1056Google Scholar
  30. Mahmoud MA, El-Shafei MA, Mtta R, Hany AA (2002) Parasitological and immunological changes in murine hepatic schistosomiasis before and after praziquantel treatment. J Egypt Soc Parasitol 32(2):551–560Google Scholar
  31. Martins-Leite P, Gazzinelli G, Alves-Oliveira LF, Gazzinelli A, Malaquias LC, Correa-Oliveira R, Teixeira-Carvalho A, Silveira AM (2008) Effect of chemotherapy with praziquantel on the production of cytokines and morbidity associated with schistosomiasis mansoni. Antimicrob Agents Chemother 52(8):2780–2786CrossRefPubMedCentralGoogle Scholar
  32. Mata-Santos HA, Lino FG, Rocha CC, Pyrrho SA (2010) Silymarin treatment reduces granuloma and hepatic fibrosis in experimental schistosomiasis. Parasitol Res 107(6):1429–1434CrossRefGoogle Scholar
  33. Mata-Santos HA, Dutra FF, Rocha CC, Lino FG, Xavier FR, Chinalia LA, Hossy BH, Castelo-Branco MT, Teodoro AJ, Paiva CN, dos Santos Pyrrho A (2014) Silymarin reduces profibrogenic cytokines and reverses hepatic fibrosis in chronic murine schistosomiasis. Antimicrob Agents Chemother 58(4):2076–2083CrossRefPubMedCentralGoogle Scholar
  34. Morais CNL, Souza JR, Melo WG, Aroucha ML, Domingues ALC, Wynn T, Abath FGC, Montenegro SML (2002) Studies on the production and regulation of interleukin, IL-13, IL-4 and interferon-γ in human schistosomiasis mansoni. Mem Inst Oswaldo Cruz 97(1):113–114CrossRefGoogle Scholar
  35. Rabia I, Nagy F, Aly E, Mohamed A, El-Assal F, El-Amir A (2010) Effect of treatment with antifibrotic drugs in combination with PZQ in immunized Schistosoma mansoni-infected murine model. J Am Sci 6:208–216Google Scholar
  36. Silva LM, Menezes RM, De Oliveira SA, Andrade ZA (2003) Chemotherapeutic effects on larval stages of Schistosoma mansoni during infection and reinfection of mice. Rev Soc Braz Med Trop 36(3):335–341CrossRefGoogle Scholar
  37. Silva LM, Oliveira SA, Ribeiro-dos-Santos R, Andrade ZA, Soares MBP (2004) Comparison of immune responses of Schistosoma mansoni-infected mice with distinct chronic forms of the disease. Acta Trop 91(2):189–196CrossRefGoogle Scholar
  38. Trapoliere M, Caligiuri A, Schmid M, Bertalani C, Failli P, Vizzutti F, Pinzani M (2009) Silybin, a component of silymarin, exerts anti-inflammatory and antifibrogenic effects on human hepatic stellate cels. J Hepatol 50(6):1102–1111CrossRefGoogle Scholar
  39. Utzinger J, Keiser J (2004) Schistosomiasis and soil-transmitted helminthiasis: common drugs for treatment and control. Expert Opin Pharmacother 5(2):263–285CrossRefGoogle Scholar
  40. Van Deventer SJ (1997) Tumor necrosis factor and Crohn’s disease. Gut 40(4):443–448CrossRefPubMedCentralGoogle Scholar
  41. Von Lichtenberg FC (1962) Host response to eggs of Schistosoma mansoni. I Granuloma formation in the unsensitized laboratory mouse. Am J Pathol 41(6):711–731PubMedCentralGoogle Scholar
  42. Williams DL, Asahi H, Botkin DJ, Stadecker MJ (2001) Schistosome infection stimulates host CD4+ T helper cell and B-cell responses against a novel egg antigen, thioredoxin peroxidase. Infect Immun 69(2):1134–1141CrossRefPubMedCentralGoogle Scholar
  43. Wu JW, Lin LC, Tsai TH (2009) Drug-drug interactions of silymarin on the perspective of pharmacokinetics. J Ethnopharmacol 121(2):185–193CrossRefGoogle Scholar
  44. Zhang L, Yao H, Cao X, Yu Y, Chen H, Li M (1999) Effects of IFN-gamma gene-modified hepatocytes on TGF-beta 1 and its receptor in mice infected with Schistosoma japonicum. Zhongguo Ji Sheng Chong 17(6):330–333Google Scholar
  45. Zhang BB, Jiao YW, Cai WM, Tao J, Liu RH (2004) Influence of interferon gamma treatment on expression of TGF-beta1 and its receptors in liver fibrosis of mice with schistosomiasis japonica. Xue Yu Ji Sheng Chong 22(6):340–343Google Scholar
  46. Zhu H, Zeng L, Zhu D, Yuan Y (2000) The role of TGF-beta 1 in mice hepatic fibrosis by schistosomiasis japonica. J Tongji Med Univ 20(4):320–329CrossRefGoogle Scholar

Copyright information

© Indian Society for Parasitology 2014

Authors and Affiliations

  • Nagwa Mostafa El-Sayed
    • 1
  • Ghada Mahmoud Fathy
    • 2
  • Sara Abdel-Rahman Abdel-Rahman
    • 2
  • Mahmoud Abdel-Atei El-Shafei
    • 3
  1. 1.Parasitology DepartmentResearch Institute of Ophthalmology, Ministry of Scientific Research & TechnologyGizaEgypt
  2. 2.Parasitology DepartmentFaculty of Medicine, Zagazig UniversityZagazigEgypt
  3. 3.Clinical Pathology DepartmentFaculty of Medicine, Zagazig UniversityZagazigEgypt

Personalised recommendations